ProBioGen Licenses GlymaxX® Technology to Bayer
BERLIN, Germany, September 10, 2019 / B3C newswire / -- ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the GlymaxX® …